Giovanni A. Salamano M.D. ⚕️🎓
LightNews LightNews
banner
gsalamano.bsky.social
Giovanni A. Salamano M.D. ⚕️🎓
@gsalamano.bsky.social
74 followers 21 following 9 posts
At 65 y.o. I’m exploring new science topics and I hope in a better future for humans. Thanks to my medical studies course that shaped my brain in a right manner 👨🏼‍⚕️⚕️💭📒 (📚)
Posts Replies Media Videos
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Brain-Penetrant Enzyme Therapy for MPS II nej.md/3Y5bAxp

Talquetamab and Teclistamab for Extramedullary Myeloma (RedirecTT-1 phase 2 study) nej.md/4pKghIv

Subscribe to NEJM for the latest medical research: nej.md/subscribe
January 1, 2026 at 2:34 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Noninferiority of One HPV Vaccine Dose to Two Doses (ESCUDDO trial) nej.md/49OEzg1

High-Dose Rifampin in Tuberculous Meningitis (HARVEST phase 3 trial) nej.md/49iiDsQ

Subscribe to NEJM for the latest medical research: nej.md/subscribe
December 18, 2025 at 2:01 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Ticagrelor and Aspirin after Coronary Surgery (TACSI trial) nej.md/45OjEWN

Disitamab Vedotin plus Toripalimab in Urothelial Cancer (RC48-C016 phase 3 trial) nej.md/3W76VtS

Subscribe to NEJM for the latest medical research: nej.md/subscribe
December 11, 2025 at 2:02 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Pegcetacoplan in C3 Glomerulopathy and IC-MPGN (VALIANT phase 3 trial) nej.md/4pmT67G

Subscribe to NEJM for the latest medical research: nej.md/subscribe
December 4, 2025 at 2:01 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Daily Mosnodenvir as Dengue Prophylaxis nej.md/48eUJwJ

CRISPR-Cas9 Targeting ANGPTL3 nej.md/43doGvu

Engasertib in Hereditary Hemorrhagic Telangiectasia nej.md/4pz9RMC

Subscribe to NEJM for the latest medical research: nej.md/subscribe
November 27, 2025 at 2:29 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Efficacy and Safety of mRNA Influenza Vaccine (phase 3 trial) nej.md/43udoTG

Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial) nej.md/475bfP9

Subscribe to NEJM for the latest medical research: nej.md/subscribe
November 20, 2025 at 2:06 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
Orforglipron, a GLP-1 Receptor Agonist for Obesity (ATTAIN-1 phase 3 trial) nej.md/4n1nSl2

Safety and Immunogenicity of Lassa Fever Vaccine nej.md/47pstZ9

Sevabertinib in HER2-Mutant NSCLC (SOHO-01 phase 1–2 study) nej.md/476jryK

Subscribe to NEJM: nej.md/subscribe
November 6, 2025 at 2:03 PM
Reposted by Giovanni A. Salamano M.D. ⚕️🎓
nejm.org
2️⃣ DB-OTO Gene Therapy for Inherited Deafness (CHORD Study) nej.md/4o7ky8f

𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲:
3-year-old born deaf can hear 2 years after breakthrough gene therapy treatment (ABC News) nej.md/43zi3ni
DB-OTO Gene Therapy for Inherited Deafness | NEJM
Genetic deficiency of otoferlin, a protein critical to synaptic transmission by the sensory hair cells of the ear, causes congenital deafness. Medicines to treat the condition are lacking; children...
nej.md
October 31, 2025 at 3:08 PM